In United States Publish
Post Time: 2025-08-21

Chris Shibutani, Goldman Sachs anlayst, joins 'Squawk on the Street' to discuss what gives the analyst the confidence Eli Lilly and Novo Nordisk can continue to perform, what happens to the anti-obesity industry in 2030, and how the market will evolve.

Goldman Sachs Raises Target On Eli Lilly: Here's Why For Country: United States. City: Charlotte, Laredo, Omaha, Richmond, Tacoma

Tag: #Please Click The Following Post, #Read the Full Piece of writing, #Read Home , #view publisher site, #mouse click the next internet page